New drug trial aims to calm IBS-Related diarrhea and pain
NCT ID NCT07574320
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether ramosetron, a drug that affects gut serotonin, can improve symptoms in people with diarrhea-predominant IBS. Seventy-six adults aged 18–65 will receive either ramosetron or a placebo daily for four weeks, along with a low-FODMAP diet and lifestyle advice. Researchers will measure changes in IBS symptom severity scores at 4 and 8 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ramosetron
- What this could lead to
- If it works, this could offer a new option to reduce abdominal pain, bloating, and diarrhea in people with IBS-D.
- What could go wrong
- This is a small, early-stage trial with only 76 participants. The drug may not work better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IBS-D (DIARRHEA-PREDOMINANT) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.